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Natural hosts for simian immunodeficiency virus (SIV) can be, and are often naturally, infected with species-
specific SIVs, but do not develop acquired immunodeficiency syndrome (AIDS). These natural hosts maintain
high SIV viral loads, but avoid immunodeficiency. Elucidating the mechanisms that allow natural hosts to
coexist with SIVwithout overt diseasemay provide crucial information for understanding AIDS pathogenesis.
Over the past few years, several key features of natural SIV infections have been described in studies con-
ducted predominantly in sooty mangabeys (SMs), African green monkeys (AGMs), and mandrills. Natural
SIV hosts are able to avoid the chronic, generalized immune system activation that is associatedwith disease
progression in HIV-infected individuals and are known to downmodulate the expression of the receptors for
SIV. In this perspective we propose that a critical factor that differentiates nonprogressive from progressive
HIV or SIV infection is the maintenance of T cell immune competence in the face of a virus that infects and
kills CD4+ T cells. Elucidation of the mechanisms underlying the preservation of immune function during
and after the acute phase of natural SIV infection may lead to the design of novel preventive and therapeutic
interventions for treatment of chronic HIV infection.The lentiviruses that cause immunodeficiency in humans and
Asian macaques originated from cross-species transmission of
viruses that naturally infect nonhuman primates in Africa (Hahn
et al., 2000). These simian immunodeficiency viruses (SIV)
belong to the group of lentiviruses that infect a wide range of
nonhuman primate (NHP) species. Both SIV infection of Asian
macaques and HIV-1 infection of humans result in a chronic
infection, and the majority of individuals progress to acquired
immunodeficiency syndrome (AIDS). In contrast, SIV-infected
natural hosts generally do not progress to AIDS, with very limited
reports of AIDS in natural hosts after almost two decades of
SIV infection (Ling et al., 2004). It would seem likely that natural
hosts of SIV have coevolved with the virus to avoid disease
progression, so dissecting the mechanisms underlying the non-
progressive nature of natural SIV infection could lead to a better
understanding of the aspects of HIV infection responsible for
the progressive nature of the disease in humans (Hirsch, 2004;
Pandrea et al., 2008b; Silvestri et al., 2007). Although there
havebeenmajor strides in the unraveling of virological and immu-
nological mechanisms underlying the nonpathogenic nature of
SIV infections, a complete understanding is lacking. We propose
a number of testable hypotheses that might account for the
nonpathogenic nature of natural SIV infections.
Many studies have added to our understanding of key similar-
ities and differences between natural nonprogressive and
progressive HIV and SIV infections. These studies have high-
lighted potential explanations for the lack of disease progression
in SIV-infected natural hosts. Importantly, it is clear that immuno-
logical control, in terms of a virus-specific T cell and B cell
response, does not account for the lack of disease progression.
Indeed, SIV-infected natural hosts maintain high plasma viralloads (based on amounts of viral RNA) (Goldstein et al., 2000,
2006; Pandrea et al., 2006a, 2006b; Silvestri et al., 2003) and
they do not exhibit superior cellular control of viremia compared
to HIV-infected humans or SIV-infected rhesus macaques (RM)
(Dunham et al., 2006).
The lentiviruses that infect natural hosts are themselves clearly
pathogenic in certain contexts; indeed, SIV infection of African
green monkeys (AGM) and Sooty mangabeys (SM) has been
associated with more rapid death of infected cells in vivo
(Gordon et al., 2008; Klatt et al., 2008; Pandrea et al., 2008a).
Moreover, SIVagm, which naturally infects AGM, can be used
to infect pigtail macaques who subsequently develop simian
AIDS (Goldstein et al., 2005; Hirsch et al., 1995) and isolates of
SIVsmm, which naturally infects SM, also cause progressive
infection in RM (Fultz et al., 1989; Hirsch et al., 1997; Li et al.,
1992; Watson et al., 1997). Therefore, the lack of disease
progression in natural hosts is unlikely to be attributable to infec-
tion with nonpathogenic viruses. However, analysis of certain
viral accessory proteins, such as nef, has led to the suggestion
that differential downregulation of certain key surface proteins
on infected cells or differential recruitment of immune activation
adaptor proteins or binding to host restriction factors by SIV-
specific nef variants could influence disease progression (Arhel
and Kirchhoff, 2009).
A fundamental difference between progressive SIV or HIV
infection and nonprogressive SIV infection is the absence of
immune activation during the chronic phase of infection in
natural hosts (Chakrabarti et al., 2000; Pandrea et al., 2003,
2006a, 2007b; Silvestri et al., 2003; Sumpter et al., 2007).
The importance of this observation rests on the findings that
chronic systemic immune activation is associated with diseaseImmunity 32, June 25, 2010 ª2010 Elsevier Inc. 737
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of outcome than plasma viral load (Deeks et al., 2004; Giorgi
et al., 1999; Rodriguez et al., 2006). The lack of immune activa-
tion during the chronic phase of natural SIV infection is therefore
thought to be critical for the nonprogressive nature of the
infection (Silvestri, 2005; Silvestri et al., 2007) but might be
somewhat surprising given that natural hosts mount a robust
immune response, including production of type I interferons
and increased frequencies of activated T cells, during the
acute phase of SIV infection (Bosinger et al., 2009; Jacquelin
et al., 2009). Moreover, in vitro production of type I interferons
by SIVagm-stimulated AGM plasmacytoid dendritic cells are
enhanced compared to SIVagm stimulation of RM plasmacytoid
dendritic cells, whereas such innate immune responses to SIV-
mac are greater in RM compared to AGM (Jacquelin et al.,
2009). However, in contrast to SIV or HIV infection of RM and
humans, respectively, this immune activation resolves toward
the end of the acute phase of infection in vivo in the natural
hosts, and may be in part due to differential upregulation of the
membrane receptor programmed death 1 observed in vivo in
lymph nodes of acutely infected natural hosts (Estes et al.,
2008) and TNF related apoptosis-inducing ligand observed after
in vitro infections (Kim et al., 2007).
Several studies have tried to elucidate the mechanisms
underlying the differential immune activation in progressive and
natural HIV and SIV infections. It has recently been shown that
one cause of immune activation during the chronic phase of
progressive infection is microbial translocation (Baroncelli
et al., 2009; Brenchley et al., 2006b; Ciccone et al., 2010;
Funderburg et al., 2010), which refers to the translocation of
microbial products from the lumen of the intestinal tract into
the systemic circulation. Microbial products can directly stimu-
late the immune system via interactions with pattern recognition
receptors such as Toll-like receptors. Indeed, elevated amounts
of soluble CD14, a protein produced by LPS-stimulated macro-
phages and monocytes, in the plasma of chronically HIV-
infected individuals, suggest that macrophages and monocytes
are directly stimulated by LPS in vivo (Brenchley et al., 2006b).
Moreover, elevated amounts of translocated microbial products
are associated with immune activation of both the adaptive
and innate arms of the immune system during the chronic phase
of progressive HIV or SIV infection (Brenchley et al., 2006b).
In stark contrast, microbial products are present at only very
low amounts in chronically SIV-infected AGM (Pandrea et al.,
2007b) and SM (Brenchley et al., 2006b) even in the presence
of high viral loads. Thus, the lack of microbial translocation
may in part account for the lack of systemic immune activation.
The mechanisms underlying microbial translocation during
the chronic phase of progressive HIV or SIV infection and the
lack thereof in nonprogressive infection remain unclear but
several plausible explanations exist. Massive damage to many
components of themucosal barrier of the GI tract, both immuno-
logic and structural, occurs in the acute phase of the infection
and persists through to the chronic phase in progressive HIV
and SIV infection. Enteropathy with increased intestinal perme-
ability has been routinely observed in chronically HIV-infected
individuals (Bjarnason et al., 1996; Kapembwa et al., 1991; Kotler
et al., 1984) and considerable enterocyte apoptosis is observed
during the acute phase of SIV infection in RM (Li et al., 2008). In738 Immunity 32, June 25, 2010 ª2010 Elsevier Inc.addition there is massive infection and loss of CD4+ T cells,
particularly from the lamina propria, in acute infection of RM
and humans (Brenchley et al., 2004; Guadalupe et al., 2003;
Mehandru et al., 2004; Veazey et al., 1998). Thus, it has been
proposed that the structural and immunologic damage to the
gut in progressive HIV and SIV infection allows for microbial
translocation to increase and contribute to persistent immune
activation even though the high viral loads of the acute phase
wane as the infected individual enters the chronic phase of the
infection (Brenchley et al., 2006a; Pandrea et al., 2008b). Indeed,
the consequences of such microbial translocation might offset
any normal physiological attempts at immunological resolution
of the acute immune activation that is probably driven in large
part by high viral loads.
One might expect, therefore, that SIV-associated damage to
the GI tract is minimal in natural hosts compared to hosts with
progressive disease. Yet, recent studies actually demonstrated
a substantial reduction in the frequency of CD4+ T cells at the
mucosal surfaces of acutely SIV-infected SM (Gordon et al.,
2007) and AGM (Pandrea et al., 2007b). However, more detailed
analyses have revealed both quantitative and qualitative differ-
ences in CD4+ T cell depletion between natural and nonnatural
hosts that highlight the importance of target cell availability and
depletion in determining disease progression. As mentioned
above, several studies have shown that natural hosts differen-
tially regulate the cell surface receptors for SIV. CD4+ T cells in
all species of natural hosts that have been studied thus far
have been shown to express very low amounts of CCR5whereas
CD8+ T cells appear to express CCR5 amounts comparable to
those in humans and RM (Pandrea et al., 2007a). Whereas
such low expression of CCR5 by CD4+ T cells has been sug-
gested as a mechanism underlying the lack of vertical transmis-
sion in natural hosts (Pandrea et al., 2007a), one might also
expect that low CCR5 expression would translate to reduced
target cell availability, particularly in the GI tract. However, given
the lack of disease progression in natural hosts, the biological
relevance of the lack of vertical transmission remains unclear
and requires further studies of infection in infant natural hosts.
Importantly, in addition to low amounts of CCR5, AGM downre-
gulate CD4 expression as naive CD4+ T cells are activated to
enter the memory T cell pool (Beaumier et al., 2009). The func-
tional properties usually associated with memory CD4+ T cells
are assumed by these CD4-negative T cells, thus ensuring the
immunocompetence of AGM. The consequence of CD4 downre-
gulation in these natural hosts would be a reduction in the avail-
ability of target cells for SIV infection. Indeed, uninfected healthy
adult AGM have few memory CD4+ T cells circulating or in the
tissues (Beaumier et al., 2009; Pandrea et al., 2007b) and SM
have less overall CD4+ T cell depletion upon SIV infection
compared to either HIV-infected humans (Brenchley et al.,
2004) or SIV-infected RM (Brenchley and Douek, 2008; Picker
et al., 2004; Veazey et al., 1998). Thus, whereas depletion of
CCR5+ CD4+ T cells in SIV-infected natural hosts may be impor-
tant in terms of frequency within that subset (whatever CCR5+
CD4+ T cells targets exist are rapidly lost), their depletion in
terms of absolute numbers, or frequency within the total T cell
pool, may actually be so minimal that it is of no physiological
or pathogenic consequence (Figure 1). However, natural or
experimental SIVsmm infection of sooty mangabeys with a rare
Figure 1. Frequencies of CCR5+CD4+ T Cells in Progressive
and Nonprogressive Infections
Depletion of GI tract CCR5+ CD4+ T cells during the acute and chronic phases
of HIV in humans (black line) and SIV in rhesus macaques (red line), sooty
mangabeys (blue line), and African green monkeys (green line). Graphs are
based upon published data. Neither African green monkeys nor sooty manga-
beys (naturally infected animals that do not progress to AIDS) are as dramat-
ically depleted of their initial GI tract CD4+ T cell populations during the acute
phase of infection as are SIV-infected rhesus macaques or HIV-infected
humans. African green monkeys and sooty mangabeys have very low frequen-
cies of CCR5+CD4+ T cells prior to infection, unlike humans and rhesus
macaques. Moreover, progressive depletion of GI tract CCR5+CD4+ T cells
does not seem to occur in SIV-infected sooty mangabeys and African green
monkeys during the chronic phase of infection.
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mucosal and peripheral CD4+ T cells with no apparent suscepti-
bility to opportunistic infections (Milush et al., 2007). The mech-
anisms by which these animals preserve immunological function
and avoid disease progression remain unclear.
In addition to these quantitative differences, there may be
qualitative differences in CD4+ T cell depletion that may con-
tribute to the lack of disease progression in natural hosts.
Indeed, recent studies have shown that CD4+ T cells producing
IL-17 (Th17 cells) are preferentially depleted from gastrointes-
tinal tracts of chronically HIV-infected humans (Brenchley
et al., 2008) and SIV-infected RM (Cecchinato et al., 2008) but
that Th17 cells are present at healthy frequencies in the GI tracts
of chronically SIV-infected SM (Brenchley et al., 2008) and AGM
(Favre et al., 2009). Th17 cells recruit neutrophils and myeloid
cells to effector sites by inducing granulocyte-colony stimulating
factor secretion (Ye et al., 2001) and are critical to epithelial cell
regeneration in mucosal tissues (Brand et al., 2006) partly
through the induction of expression of claudins, components
of epithelial tight junctions. Th17 cells also induce epithelial cell
production of defensins and mucin, both vital to the integrity of
mucosal barrier (Chen et al., 2003; Sugimoto et al., 2008).
Thus, preferential loss of Th17 cells from the GI tract during
progressive HIV and SIV infections might lead to reduced struc-
tural and immunologic integrity of the mucosal barrier with
a consequent increase in microbial translocation. Conversely,
their preservation in SIV-infected natural hosts may partly
explain the lack of microbial translocation observed in such
animals. Therapeutic interventions (such as IL-23 and retinoicacid, which aim to increase Th17 cell frequencies in progressive
infection, and IL-1 receptor antagonists, which aim to decrease
Th17 cell frequencies in nonprogressive infections) could shed
further light on the biological significance of Th17 cells in the
maintenance of the tight epithelial barrier of the GI tract and
microbial translocation. Epithelial damage could, in turn, also
lead to decreased production of secretory IgA leading to
decreased clearance of translocated microbial products.
Although recent studies have clearly demonstrated increased
enteroycte apoptosis during the acute phase of SIV infection
(Li et al., 2008), the mechanisms underlying this enterocyte
apoptosis are unclear. Potential mechanisms underlying entero-
cyte apoptosis could involve lentiviral envelope proteins binding
to oligosaccharide moieties present on a G-coupled receptor
GPR15 (Maresca et al., 2003), and recent studies have impli-
cated TNF in the HIV-mediated enterocyte damage (Nazli
et al., 2010).
Thus, we propose that a critical factor that differentiates
nonprogressive from progressive HIV or SIV infection is the
maintenance of T cell immune competence during and after
the acute phase of disease in the face of a virus that infects
and kills CD4+ T cells. Hence, natural hosts may have adopted
mechanisms by which target cell availability for SIV is reduced
while immunological function is maintained by subsets of
T cells that are resistant to infection. Importantly, downregulation
of CCR5 by all natural host species studied and downregulation
of CD4 by AGM occurs irrespective of SIV infection. Although
the molecular mechanisms by which CD4 in AGM and CCR5 in
all natural hosts are differentially expressed compared to other
primate species remain unclear, these findings suggest the
coevolution of natural hosts with SIV.
The mitigation of lentivirus infection of CD4+ T cells through
downregulation of the receptors for the virus raises an interesting
paradox that clearly needs some explanation, namely: how are
high plasma virus loads maintained in natural hosts if target
cell availability has been reduced? In both natural hosts and
hosts with progressive infection an equilibrium is set up between
the availability of target cells, the depletion of target cells, and
the production of infectious virions. In progressive disease, this
equilibrium is unstable and decays toward a state of loss of
immune competence related to the reduced provision of effector
memory CD4+ T cells that protect from pathogens that define
AIDS. In contrast, this equilibrium appears to be maintained for
the normal lifespan of natural hosts with no apparent detriment
to their health. We propose that such a stable equilibrium may
be achieved through the ‘‘uncoupling’’ of virus production from
the processes that lead to disease progression. To understand
how this might occur, we should first consider the maturation
of CD4+ T cells into their different subsets. Upon stimulation
through the TCR, naive CD4+ T cells may mature into different
memory T cell subsets as shown in Figure 2 (top). Central
memory T cells are thought to have stem cell-like qualities in
that they may be regarded as a self-renewing source of effector
memory and activated T cells (van Grevenynghe et al., 2008).
Central memory T cells tend to be localized to organized
lymphoid tissues such as lymph nodes and gastrointestinal
Peyer’s patches, whereas effector memory T cells tend to be
localized to peripheral tissues such as the broncoalveolar fluid
and gastrointestinal lamina propria. Both of these T cell subsetsImmunity 32, June 25, 2010 ª2010 Elsevier Inc. 739
Figure 2. Uncoupling of Disease Progression from Virus Production
Top: In an uninfected host, naive CD4+ T cells mature into central memory
(CCR7+CD62L+, markers not shown). CD4+ T cells that may be regarded as
having self-renewing potential. Effector memory CD4+ T cells (defined as
CCR7CD62L) and activated CD4+ T cells are more prone to activation-
induced cell death.
Center: In an HIV- or SIV-infected host that progresses to AIDS, the infection
and death of central memory CD4+ T cells eventually depletes this important
cellular source and results in disease progression to AIDS. The infection and
death of effector memory and activatedCD4+ T cells produces the bulk of virus
but makes little impact on these cellular pools because they are nonetheless
destined to die by AICD.
Bottom: In nonprogressive SIV infection of natural hosts, virus load is main-
tained by the infection of effector memory and activated CD4+ T cells. The
resistance of the central memory CD4+ T cells (defined as CCR7+CD62L+) to
infection, by coreceptor downregulation, prevents their depletion, thus
ensuring immune competence and precluding disease progression.
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would result in the production of small numbers of virions.
However, activated memory T cells, defined by the expression
of Ki67, may produce up to 6-fold more virions per cell (Reilly
et al., 2007). Thus the target cells responsible for the production
of the majority of virions in a chronically infected individual would740 Immunity 32, June 25, 2010 ª2010 Elsevier Inc.be contained within the activatedmemory T cell subset (Figure 2,
center and bottom). Indeed, it has been shown that the avail-
ability of activated CD4+ T cells in naturally SIV-infected sooty
mangabeys dictates the degree of viremia (Figure 2, bottom;
Klatt et al., 2008). When compared to central memory T cells,
both effector memory and activated memory T cells have a far
greater tendency to activation-induced cell death; thus, theoret-
ically, their death from viral infection should not have a great
impact on their steady-state numbers while enabling the produc-
tion of great quantities of virions. By contrast, the loss of T cells
from central memory pool would, over time, severely limit the
numbers of effector memory and activated memory T cells avail-
able to control pathogens in the tissues. Thus it is the loss of
central memory CD4+ T cells that introduces instability into the
equilibrium between the availability of target cells, the depletion
of target cells, and the production of infectious virions, and
progression to AIDS occurs because of the eventual failure of
the provision of effector memory CD4+ T cells to the tissues
(Okoye et al., 2007).
Thus one might consider HIV and SIV infection as having two
separable components: disease progression, which is depen-
dent on infection and depletion of central memory CD4+
T cells, and virus production, which is dependent on infection
of activated memory T cells. A survival mechanism could there-
fore have evolved in natural hosts to uncouple disease progres-
sion from virus production by reducing infection and depletion of
central memory CD4+ T cells while maintaining viral loads
through infection of activated CD4+ T cells (Figure 2, bottom;
Paiardini et al., 2009). The critical aspect of such uncoupling is
to alter target cell availability and we have described above
how this has been achieved in AGM and SM by two different
mechanisms. In progressive disease of RM and humans, any
activating stimuli generate target cells within the central memory
T cell population by increasing CCR5 expression, whereas in
natural hosts any activating stimuli remove target cells from
central memory CD4+ T cells by reducing CCR5 in SM and
CD4 in AGM, thus preserving this critical T cell subset while
maintaining effector cells that produce virus and thus maintain
plasma viral loads. However, the amount of virus production
by individual subsets of CD4+ T cells in progressive and nonpro-
gressive infections is not well understood. Thus, one critical
question that must be further investigated is how much virus is
produced from given infected CD4+ T cell subsets in order to
maintain particular viral loads in different hosts.
Although it is unlikely that humans will be afforded the same
experiment of nature that has allowed natural hosts to avoid
disease progression (nor should they), we can nevertheless
apply the lessons learned from the study of these animals to
novel therapeutic avenues. Clearly, reduction of target cell avail-
ability is one such goal and CCR5 blockers such as maraviroc
could be viewed as approximating the consequences of CCR5
downregulation in SM. Moreover, understanding the molecular
mechanisms underlying target cell availability, downregulation
of immune activation after the acute phase of infection, differen-
tial expression of SIV and HIV receptors and coreceptors, and
maintenance of immunological function by natural hosts will
inevitably lead to a better understanding of the lack of disease
progression in natural hosts and to the development of novel
adjunctive therapeutic interventions for HIV-infected humans.
Immunity
PerspectiveREFERENCES
Arhel, N.J., and Kirchhoff, F. (2009). Implications of Nef: Host cell interactions
in viral persistence and progression to AIDS. Curr. Top. Microbiol. Immunol.
339, 147–175.
Baroncelli, S., Galluzzo, C.M., Pirillo, M.F., Mancini, M.G., Weimer, L.E.,
Andreotti, M., Amici, R., Vella, S., Giuliano, M., and Palmisano, L. (2009).
Microbial translocation is associated with residual viral replication in HAART-
treated HIV+ subjects with <50copies/ml HIV-1 RNA. J. Clin. Virol. 46,
367–370.
Beaumier, C.M., Harris, L.D., Goldstein, S., Klatt, N.R., Whitted, S., McGinty,
J., Apetrei, C., Pandrea, I., Hirsch, V.M., and Brenchley, J.M. (2009). CD4
downregulation by memory CD4+ T cells in vivo renders African green
monkeys resistant to progressive SIVagm infection. Nat. Med. 15, 879–885.
Bjarnason, I., Sharpstone, D.R., Francis, N., Marker, A., Taylor, C., Barrett, M.,
Macpherson, A., Baldwin, C., Menzies, I.S., Crane, R.C., et al. (1996). Intestinal
inflammation, ileal structure and function in HIV. AIDS 10, 1385–1391.
Bosinger, S.E., Li, Q., Gordon, S.N., Klatt, N.R., Duan, L., Xu, L., Francella, N.,
Sidahmed, A., Smith, A.J., Cramer, E.M., et al. (2009). Global genomic analysis
reveals rapid control of a robust innate response in SIV-infected sooty manga-
beys. J. Clin. Invest. 119, 3556–3572.
Brand, S., Beigel, F., Olszak, T., Zitzmann, K., Eichhorst, S.T., Otte, J.-M.,
Diepolder, H., Marquardt, A., Jagla, W., Popp, A., et al. (2006). IL-22 is
increased in active Crohn’s disease and promotes proinflammatory gene
expression and intestinal epithelial cell migration. Am. J. Physiol. Gastrointest.
Liver Physiol. 290, G827–G838.
Brenchley, J.M., and Douek, D.C. (2008). The mucosal barrier and immune
activation in HIV pathogenesis. Curr. Opin. HIV AIDS 3, 356–361.
Brenchley, J.M., Schacker, T.W., Ruff, L.E., Price, D.A., Taylor, J.H., Beilman,
G.J., Nguyen, P.L., Khoruts, A., Larson, M., Haase, A.T., and Douek, D.C.
(2004). CD4+ T cell depletion during all stages of HIV disease occurs predom-
inantly in the gastrointestinal tract. J. Exp. Med. 200, 749–759.
Brenchley, J.M., Price, D.A., and Douek, D.C. (2006a). HIV disease: Fallout
from a mucosal catastrophe? Nat. Immunol. 7, 235–239.
Brenchley, J.M., Price, D.A., Schacker, T.W., Asher, T.E., Silvestri, G., Rao, S.,
Kazzaz, Z., Bornstein, E., Lambotte, O., Altmann, D., et al. (2006b). Microbial
translocation is a cause of systemic immune activation in chronic HIV infection.
Nat. Med. 12, 1365–1371.
Brenchley, J.M., Paiardini, M., Knox, K.S., Asher, A.I., Cervasi, B., Asher, T.E.,
Scheinberg, P., Price, D.A., Hage, C.A., Kholi, L.M., et al. (2008). Differential
Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infec-
tions. Blood 112, 2826–2835.
Cecchinato, V., Trindade, C., Laurence, A., Heraud, J., Brenchley, J., Ferrari,
M., Zaffiri, L., Tryniszewska, E., Tsai, W., Vaccari, M., et al. (2008). Altered
balance between Th17 and Th1 cells at mucosal sites predicts AIDS progres-
sion in simian immunodeficiency virus-infected macaques. Mucosal Immunol.
1, 279–288.
Chakrabarti, L.A., Lewin, S.R., Zhang, L., Gettie, A., Luckay, A., Martin, L.N.,
Skulsky, E., Ho, D.D., Cheng-Mayer, C., and Marx, P.A. (2000). Normal
T-cell turnover in sooty mangabeys harboring active simian immunodeficiency
virus infection. J. Virol. 74, 1209–1223.
Chen, Y., Thai, P., Zhao, Y.H., Ho, Y.S., DeSouza, M.M., and Wu, R. (2003).
Stimulation of airway mucin gene expression by interleukin (IL)-17 through
IL-6 paracrine/autocrine loop. J. Biol. Chem. 278, 17036–17043.
Ciccone, E.J., Read, S.W., Mannon, P.J., Yao, M.D., Hodge, J.N., Dewar, R.,
Chairez, C.L., Proschan,M.A., Kovacs, J.A., and Sereti, I. (2010). Cycling of gut
mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is
associated with plasma LPS levels. Mucosal Immunol. 3, 172–181.
Deeks, S.G., Kitchen, C.M., Liu, L., Guo, H., Gascon, R., Narvaez, A.B., Hunt,
P., Martin, J.N., Kahn, J.O., Levy, J., et al. (2004). Immune activation set point
during early HIV infection predicts subsequent CD4+ T-cell changes indepen-
dent of viral load. Blood 104, 942–947.
Dunham, R., Pagliardini, P., Gordon, S., Sumpter, B., Engram, J., Moanna, A.,
Paiardini, M., Mandl, J.N., Lawson, B., Garg, S., et al. (2006). The AIDS resis-
tance of naturally SIV-infected sooty mangabeys is independent of cellular
immunity to the virus. Blood 108, 209–217.Estes, J.D., Gordon, S.N., Zeng, M., Chahroudi, A.M., Dunham, R.M.,
Staprans, S.I., Reilly, C.S., Silvestri, G., andHaase, A.T. (2008). Early resolution
of acute immune activation and induction of PD-1 in SIV-infected sooty
mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus
macaques. J. Immunol. 180, 6798–6807.
Favre, D., Lederer, S., Kanwar, B., Ma, Z.M., Proll, S., Kasakow, Z., Mold, J.,
Swainson, L., Barbour, J.D., Baskin, C.R., et al. (2009). Critical loss of the
balance between Th17 and T regulatory cell populations in pathogenic SIV
infection. PLoS Pathog. 5, e1000295.
Fultz, P.N., McClure, H.M., Anderson, D.C., and Switzer, W.M. (1989). Identi-
fication and biologic characterization of an acutely lethal variant of simian
immunodeficiency virus from sooty mangabeys (SIV/SMM). AIDS Res. Hum.
Retroviruses 5, 397–409.
Funderburg, N.T., Mayne, E., Sieg, S.F., Asaad, R., Jiang, W., Kalinowska, M.,
Luciano, A.A., Stevens, W., Rodriguez, B., Brenchley, J.M., et al. (2010).
Increased tissue factor expression on circulating monocytes in chronic HIV
infection: Relationship to in vivo coagulation and immune activation. Blood
115, 161–167.
Giorgi, J.V., Hultin, L.E., McKeating, J.A., Johnson, T.D., Owens, B.,
Jacobson, L.P., Shih, R., Lewis, J., Wiley, D.J., Phair, J.P., et al. (1999). Shorter
survival in advanced human immunodeficiency virus type 1 infection is more
closely associated with T lymphocyte activation than with plasma virus burden
or virus chemokine coreceptor usage. J. Infect. Dis. 179, 859–870.
Goldstein, S., Ourmanov, I., Brown, C.R., Beer, B.E., Elkins, W.R., Plishka, R.,
Buckler-White, A., and Hirsch, V.M. (2000). Wide range of viral load in healthy
african green monkeys naturally infected with simian immunodeficiency virus.
J. Virol. 74, 11744–11753.
Goldstein, S., Ourmanov, I., Brown, C.R., Plishka, R., Buckler-White, A.,
Byrum, R., and Hirsch, V.M. (2005). Plateau levels of viremia correlate with
the degree of CD4+-T-cell loss in simian immunodeficiency virus SIVagm-
infected pigtailed macaques: Variable pathogenicity of natural SIVagm
isolates. J. Virol. 79, 5153–5162.
Goldstein, S., Brown, C.R., Ourmanov, I., Pandrea, I., Buckler-White, A., Erb,
C., Nandi, J.S., Foster, G.J., Autissier, P., Schmitz, J.E., and Hirsch, V.M.
(2006). Comparison of simian immunodeficiency virus SIVagmVer replication
and CD4+ T-cell dynamics in vervet and sabaeus African green monkeys.
J. Virol. 80, 4868–4877.
Gordon, S.N., Klatt, N.R., Bosinger, S.E., Brenchley, J.M., Milush, J.M.,
Engram, J.C., Dunham, R.M., Paiardini, M., Klucking, S., Danesh, A., et al.
(2007). Severe depletion of mucosal CD4+ T cells in AIDS-free simian immuno-
deficiency virus-infected sooty mangabeys. J. Immunol. 179, 3026–3034.
Gordon, S.N., Dunham, R.M., Engram, J.C., Estes, J., Wang, Z., Klatt, N.R.,
Paiardini, M., Pandrea, I.V., Apetrei, C., Sodora, D.L., et al. (2008). Short-lived
infected cells support virus replication in sooty mangabeys naturally infected
with simian immunodeficiency virus: Implications for AIDS pathogenesis.
J. Virol. 82, 3725–3735.
Guadalupe, M., Reay, E., Sankaran, S., Prindiville, T., Flamm, J., McNeil, A.,
and Dandekar, S. (2003). Severe CD4+ T-cell depletion in gut lymphoid tissue
during primary human immunodeficiency virus type 1 infection and substantial
delay in restoration following highly active antiretroviral therapy. J. Virol. 77,
11708–11717.
Hahn, B.H., Shaw, G.M., De Cock, K.M., and Sharp, P.M. (2000). AIDS as
a zoonosis: Scientific and public health implications. Science 287, 607–614.
Hirsch, V.M. (2004). What can natural infection of African monkeys with simian
immunodeficiency virus tell us about the pathogenesis of AIDS? AIDS Rev. 6,
40–53.
Hirsch, V.M., Dapolito, G., Johnson, P.R., Elkins, W.R., London, W.T., Montali,
R.J., Goldstein, S., and Brown, C. (1995). Induction of AIDS by simian immu-
nodeficiency virus from an African green monkey: Species-specific variation
in pathogenicity correlates with the extent of in vivo replication. J. Virol. 69,
955–967.
Hirsch, V., Adger-Johnson, D., Campbell, B., Goldstein, S., Brown, C., Elkins,
W.R., and Montefiori, D.C. (1997). A molecularly cloned, pathogenic, neutrali-
zation-resistant simian immunodeficiency virus, SIVsmE543-3. J. Virol. 71,
1608–1620.
Jacquelin, B., Mayau, V., Targat, B., Liovat, A.S., Kunkel, D., Petitjean, G.,
Dillies, M.A., Roques, P., Butor, C., Silvestri, G., et al. (2009). NonpathogenicImmunity 32, June 25, 2010 ª2010 Elsevier Inc. 741
Immunity
PerspectiveSIV infection of African green monkeys induces a strong but rapidly controlled
type I IFN response. J. Clin. Invest. 119, 3544–3555.
Kapembwa, M.S., Fleming, S.C., Sewankambo, N., Serwadda, D., Lucas, S.,
Moody, A., and Griffin, G.E. (1991). Altered small-intestinal permeability asso-
ciated with diarrhoea in human-immunodeficiency-virus-infected Caucasian
and African subjects. Clin. Sci. (Lond.) 81, 327–334.
Kim, N., Dabrowska, A., Jenner, R.G., and Aldovini, A. (2007). Human and
simian immunodeficiency virus-mediated upregulation of the apoptotic factor
TRAIL occurs in antigen-presenting cells from AIDS-susceptible but not from
AIDS-resistant species. J. Virol. 81, 7584–7597.
Klatt, N.R., Villinger, F., Bostik, P., Gordon, S.N., Pereira, L., Engram, J.C.,
Mayne, A., Dunham, R.M., Lawson, B., Ratcliffe, S.J., et al. (2008). Availability
of activated CD4+ T cells dictates the level of viremia in naturally SIV-infected
sooty mangabeys. J. Clin. Invest. 118, 2039–2049.
Kotler, D.P., Gaetz, H.P., Lange, M., Klein, E.B., and Holt, P.R. (1984). Enter-
opathy associated with the acquired immunodeficiency syndrome. Ann.
Intern. Med. 101, 421–428.
Li, Y., Hui, H., Burgess, C.J., Price, R.W., Sharp, P.M., Hahn, B.H., and Shaw,
G.M. (1992). Complete nucleotide sequence, genome organization, and bio-
logical properties of human immunodeficiency virus type 1 in vivo: Evidence
for limited defectiveness and complementation. J. Virol. 66, 6587–6600.
Li, Q., Estes, J.D., Duan, L., Jessurun, J., Pambuccian, S., Forster, C.,
Wietgrefe, S., Zupancic, M., Schacker, T., Reilly, C., et al. (2008). Simian
immunodeficiency virus-induced intestinal cell apoptosis is the underlying
mechanism of the regenerative enteropathy of early infection. J. Infect. Dis.
197, 420–429.
Ling, B., Apetrei, C., Pandrea, I., Veazey, R.S., Lackner, A.A., Gormus, B., and
Marx, P.A. (2004). Classic AIDS in a sooty mangabey after an 18-year natural
infection. J. Virol. 78, 8902–8908.
Maresca, M., Mahfoud, R., Garmy, N., Kotler, D.P., Fantini, J., and Clayton, F.
(2003). The virotoxin model of HIV-1 enteropathy: Involvement of GPR15/Bob
and galactosylceramide in the cytopathic effects induced by HIV-1 gp120 in
the HT-29-D4 intestinal cell line. J. Biomed. Sci. 10, 156–166.
Mehandru, S., Poles, M.A., Tenner-Racz, K., Horowitz, A., Hurley, A., Hogan,
C., Boden, D., Racz, P., and Markowitz, M. (2004). Primary HIV-1 infection is
associated with preferential depletion of CD4+ T lymphocytes from effector
sites in the gastrointestinal tract. J. Exp. Med. 200, 761–770.
Milush, J.M., Reeves, J.D., Gordon, S.N., Zhou, D., Muthukumar, A., Kosub,
D.A., Chacko, E., Giavedoni, L.D., Ibegbu, C.C., Cole, K.S., et al. (2007). Virally
induced CD4+ T cell depletion is not sufficient to induce AIDS in a natural host.
J. Immunol. 179, 3047–3056.
Nazli, A., Chan, O., Dobson-Belaire, W.N., Ouellet, M., Tremblay, M.J.,
Gray-Owen, S.D., Arsenault, A.L., and Kaushic, C. (2010). Exposure to HIV-1
directly impairs mucosal epithelial barrier integrity allowing microbial translo-
cation. PLoS Pathog. 6, e1000852.
Okoye, A., Meier-Schellersheim, M., Brenchley, J.M., Hagen, S.I., Walker,
J.M., Rohankhedkar, M., Lum, R., Edgar, J.B., Planer, S.L., Legasse, A.,
et al. (2007). Progressive CD4+ central memory T cell decline results in
CD4+ effector memory insufficiency and overt disease in chronic SIV infection.
J. Exp. Med. 204, 2171–2185.
Paiardini, M., Pandrea, I., Apetrei, C., and Silvestri, G. (2009). Lessons learned
from the natural hosts of HIV-related viruses. Annu. Rev. Med. 60, 485–495.
Pandrea, I., Onanga, R., Kornfeld, C., Rouquet, P., Bourry, O., Clifford, S.,
Telfer, P.T., Abernethy, K., White, L.T., Ngari, P., et al. (2003). High levels of
SIVmnd-1 replication in chronically infected Mandrillus sphinx. Virology 317,
119–127.
Pandrea, I., Apetrei, C., Dufour, J., Dillon, N., Barbercheck, J., Metzger, M.,
Jacquelin, B., Bohm, R., Marx, P.A., Barre-Sinoussi, F., et al. (2006a). Simian
immunodeficiency virus SIVagm.sab infection of Caribbean African green
monkeys: a new model for the study of SIV pathogenesis in natural hosts.
J. Virol. 80, 4858–4867.
Pandrea, I., Silvestri, G., Onanga, R., Veazey, R.S., Marx, P.A., Hirsch, V., and
Apetrei, C. (2006b). Simian immunodeficiency viruses replication dynamics in742 Immunity 32, June 25, 2010 ª2010 Elsevier Inc.African non-human primate hosts: Common patterns and species-specific
differences. J. Med. Primatol. 35, 194–201.
Pandrea, I., Apetrei, C., Gordon, S., Barbercheck, J., Dufour, J., Bohm, R.,
Sumpter, B., Roques, P., Marx, P.A., Hirsch, V.M., et al. (2007a). Paucity of
CD4+CCR5+ T cells is a typical feature of natural SIV hosts. Blood 109,
1069–1076.
Pandrea, I.V., Gautam, R., Ribeiro, R.M., Brenchley, J.M., Butler, I.F., Pattison,
M., Rasmussen, T., Marx, P.A., Silvestri, G., Lackner, A.A., et al. (2007b). Acute
loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency
virus virulence. J. Immunol. 179, 3035–3046.
Pandrea, I., Onanga, R., Souquiere, S., Mouinga-Ondeme, A., Bourry, O.,
Makuwa, M., Rouquet, P., Silvestri, G., Simon, F., Roques, P., and Apetrei,
C. (2008a). Paucity of CD4+ CCR5+ T cells may prevent transmission of simian
immunodeficiency virus in natural nonhuman primate hosts by breast-feeding.
J. Virol. 82, 5501–5509.
Pandrea, I., Sodora, D.L., Silvestri, G., and Apetrei, C. (2008b). Into the wild:
Simian immunodeficiency virus (SIV) infection in natural hosts. Trends Immu-
nol. 29, 419–428.
Picker, L.J., Hagen, S.I., Lum, R., Reed-Inderbitzin, E.F., Daly, L.M., Sylwester,
A.W., Walker, J.M., Siess, D.C., Piatak, M., Jr., Wang, C., et al. (2004). Insuffi-
cient production and tissue delivery of CD4+memory T cells in rapidly progres-
sive simian immunodeficiency virus infection. J. Exp. Med. 200, 1299–1314.
Reilly, C., Wietgrefe, S., Sedgewick, G., and Haase, A. (2007). Determination of
simian immunodeficiency virus production by infected activated and resting
cells. AIDS 21, 163–168.
Rodriguez, B., Sethi, A.K., Cheruvu, V.K., Mackay, W., Bosch, R.J., Kitahata,
M., Boswell, S.L., Mathews, W.C., Bangsberg, D.R., Martin, J., et al. (2006).
Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in
untreated HIV infection. JAMA 296, 1498–1506.
Silvestri, G. (2005). Naturally SIV-infected sooty mangabeys: Are we closer to
understanding why they do not develop AIDS? J. Med. Primatol. 34, 243–252.
Silvestri, G., Sodora, D.L., Koup, R.A., Paiardini, M., O’Neil, S.P., McClure,
H.M., Staprans, S.I., and Feinberg, M.B. (2003). Nonpathogenic SIV infection
of sooty mangabeys is characterized by limited bystander immunopathology
despite chronic high-level viremia. Immunity 18, 441–452.
Silvestri, G., Paiardini, M., Pandrea, I., Lederman, M.M., and Sodora, D.L.
(2007). Understanding the benign nature of SIV infection in natural hosts.
J. Clin. Invest. 117, 3148–3154.
Sugimoto, K., Ogawa, A., Mizoguchi, E., Shimomura, Y., Andoh, A., Bhan,
A.K., Blumberg, R.S., Xavier, R.J., and Mizoguchi, A. (2008). IL-22 ameliorates
intestinal inflammation in a mouse model of ulcerative colitis. J. Clin. Invest.
118, 534–544.
Sumpter, B., Dunham, R., Gordon, S., Engram, J., Hennessy, M., Kinter, A.,
Paiardini, M., Cervasi, B., Klatt, N., McClure, H., et al. (2007). Correlates of
preserved CD4(+) T cell homeostasis during natural, nonpathogenic simian
immunodeficiency virus infection of sooty mangabeys: Implications for AIDS
pathogenesis. J. Immunol. 178, 1680–1691.
van Grevenynghe, J., Procopio, F.A., He, Z., Chomont, N., Riou, C., Zhang, Y.,
Gimmig, S., Boucher, G., Wilkinson, P., Shi, Y., et al. (2008). Transcription
factor FOXO3a controls the persistence of memory CD4(+) T cells during
HIV infection. Nat. Med. 14, 266–274.
Veazey, R.S., DeMaria, M., Chalifoux, L.V., Shvetz, D.E., Pauley, D.R., Knight,
H.L., Rosenzweig, M., Johnson, R.P., Desrosiers, R.C., and Lackner, A.A.
(1998). Gastrointestinal tract as a major site of CD4+ T cell depletion and viral
replication in SIV infection. Science 280, 427–431.
Watson, A., Ranchalis, J., Travis, B., McClure, J., Sutton, W., Johnson, P.R.,
Hu, S.L., and Haigwood, N.L. (1997). Plasma viremia in macaques infected
with simian immunodeficiency virus: Plasma viral load early in infection
predicts survival. J. Virol. 71, 284–290.
Ye, P., Garvey, P.B., Zhang, P., Nelson, S., Bagby, G., Summer,W.R., Schwar-
zenberger, P., Shellito, J.E., and Kolls, J.K. (2001). Interleukin-17 and lung host
defense against Klebsiella pneumoniae infection. Am. J. Respir. Cell Mol. Biol.
25, 335–340.
